IO Frontiers World 2019


Jeffrey Evelhoch

Jeffrey Evelhoch

VP, Head of Translational Biomarkers, Merck Research Laboratories

Jeff Evelhoch is Vice President and Head of Translational Biomarkers in Translational Medicine at Merck Research Laboratories (MRL).  He received his Ph.D. in Analytical Chemistry from the University of California at Riverside in 1981 and was an NIH Postdoctoral Fellow at Washington University in St. Louis prior to joining the faculty at Wayne State University School of Medicine in 1984, where he became Professor of Internal Medicine, Oncology and Radiology.  While at Wayne State, his research centered on novel ways to use in vivo magnetic resonance to quantify tumor physiology and hemodynamics non-invasively and to predict and/or monitor tumor response to treatment.  In 2002, he began working in the biopharmaceutical industry with Pharmacia as Director of Structural Imaging and continued in that position after the acquisition of Pharmacia by Pfizer in 2003.  In 2004, Dr. Evelhoch left Pfizer for Amgen, where he was Medical Sciences Executive Director and head of Imaging Sciences, a department dedicated to the use of all imaging modalities as biomarkers in the drug development process across therapeutic areas.  In 2008, he joined MRL as Vice President and Head of Imaging to provide leadership and coordination for the use of preclinical and clinical imaging resources for all MRL therapeutic areas and functions, from discovery through late stage development. In April 2015, he was named Vice President and Head of Translational Biomarkers at MRL. In this role Jeff, leads a group of more than 100 scientists, with expertise in quantitative molecular and imaging assays, who are responsible for development and qualification of novel biomarkers, use of biomarkers to inform pipeline decisions and the development and deployment of companion diagnostic tests. Throughout his career, Dr. Evelhoch has actively published and served on National Institutes of Health review committees. Dr. Evelhoch was named a Fellow of the International Society of Magnetic Resonance in Medicine (ISMRM) in 2003. He has helped to lead the joint efforts of professional organizations, industry groups and federal agencies to further the development and use of quantitative imaging, including The Biomarker Consortium, the Quantitative Imaging Biomarker Alliance and the ISMRM Ad Hoc Committee on Standards for Quantitative Magnetic Resonance.

  • "Great venue to solidify and harmonize on the current challenges facing this sector - in real time. The caliber of the speakers and session contents was premier. “
    Dolores Baksh
    Innovation Leader, GE Healthcare
  • “A great event to learn about the hurdles that are needed to be overcome to get through the clinic.”
    Devin Bridgen
    Scientist, strategic partnerships, SQZ Biotech
  • "It was a great opportunity to share current data and thinking about the development of therapeutics directed at modulating the immune response to cancer."
    Lance Leopold
    Vice President, Head of Oncology Development, Incyte Corporation
  • "Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field."
    Dr James Trager
    Vice President, Research & Product Development, Dendreon
  • “In the rapidly moving Advanced Therapy market, Phacilitate remains one of the premier events.”
    David James
    CEO, Scinogy